<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs used to lower blood pressure in the operating room: Adult dosing*&lt;sup&gt;¶&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs used to lower blood pressure in the operating room: Adult dosing*<sup>¶</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Drugs used to lower blood pressure in the operating room: Adult dosing*<sup>¶</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="3" width="20%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1">Drug</td> <td class="subtitle1">Functional class (predominant receptor or mechanism)</td> <td class="subtitle1">Bolus dose</td> <td class="subtitle1">Infusion dose</td> <td class="subtitle1">Comments</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="5">Beta blocking agents – Generally avoided in patients with acute decompensated heart failure</td> </tr> <tr class="divider_bottom"> <td class="indent1">Esmolol</td> <td>Beta<sub>1</sub>-selective adrenergic receptor blockade</td> <td>10 to 50 mg, which may be repeated (every 5 to 15 minutes depending upon the initial dose used, the desired effect, and the patient's risk for hemodynamic decompensation)</td> <td>50 to 300 mcg/kg/minute</td> <td> <ul> <li>Rapid onset and very short duration of action</li> <li>Clearance is not dependent on renal or hepatic function due to rapid metabolism by plasma esterases</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Metoprolol</td> <td>Beta<sub>1</sub>-selective adrenergic receptor blockade</td> <td>1 to 5 mg, followed by 2.5 to 15 mg every 3 to 6 hours</td> <td>N/A</td> <td> <ul> <li>Commonly used agent to treat suspected myocardial ischemia due to tachycardia with normal or elevated blood pressure</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Labetalol</td> <td>Blockade of postsynaptic alpha<sub>1</sub>-adrenergic receptors and non-selective beta blockade for beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic receptors</td> <td>Initial bolus of 5 to 25 mg, which may be followed by repeated boluses every 10 minutes (up to 300 mg)</td> <td>0.5 to 2 mg/minute up to a maximum of 10 mg/minute (generally reserved for hypertensive emergencies)</td> <td> <ul> <li>Often selected as a first-line agent to treat concomitant hypertension and tachycardia</li> <li>Use cautiously in patients with obstructive or reactive airway disease</li> <li>Avoid in hyperadrenergic states (eg, pheochromocytoma or cocaine or methamphetamine overdose) since beta blockade and loss of beta<sub>2</sub>-mediated vasodilation induced by labetalol can lead to severe hypertension when prior alpha<sub>1</sub>-adrenergic blockade is incomplete</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="5">Calcium channel blocking agents – Use cautiously in patients with increased ICP</td> </tr> <tr class="divider_bottom"> <td class="indent1">Nicardipine*</td> <td>Selective dihydropyridine-type calcium channel blocker; selective arteriolar smooth muscle relaxation</td> <td>100 to 500 mcg</td> <td>5 to 15 mg/hour</td> <td> <ul> <li>Predominantly arteriolar vasodilator</li> <li>Commonly used for neurosurgical patients</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Clevidipine</td> <td>Selective dihydropyridine-type calcium channel blocker; selective arteriolar smooth muscle relaxation</td> <td>N/A</td> <td>Initial dose 1 to 2 mg/hour, with rapid titration up to 16 mg/hour</td> <td> <ul> <li>Rapid onset and short duration of action</li> <li>Clearance is not dependent on renal or hepatic function due to rapid metabolism by plasma esterases</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="5">Direct vasodilators (direct relaxation of vascular smooth muscle) – Generally avoided in patients with increased ICP</td> </tr> <tr class="divider_bottom"> <td class="indent1">Hydralazine</td> <td>Highly selective vasodilation of arterial resistance vessels</td> <td>Initial bolus of 2.5 mg followed by repeated boluses every 5 minutes to a maximum 20 mg</td> <td>N/A</td> <td> <ul> <li>Minimal or no effect on the venous circulation</li> <li>Relatively slow onset compared with other antihypertensive agents</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Nitroglycerin (glyceryl trinitrate)</td> <td>Nitrodilator that causes increased release of NO, resulting in smooth muscle relaxation</td> <td>10 to 40 mcg, which may be repeated and/or followed by infusion</td> <td> <p>10 to 200 mcg/minute</p> <p>or</p> 0.1 to 3 mcg/kg/minute</td> <td> <ul> <li>Continuous monitoring using an intra-arterial catheter is warranted as soon as feasible, particularly if higher doses are used</li> <li>SL or paste forms of nitroglycerin paste (1 to 2 inches) formulations also available</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Nitroprusside</td> <td>Nitrodilator that directly releases NO, resulting in smooth muscle relaxation</td> <td>N/A</td> <td> <p>10 to 200 mcg/minute</p> <p>or</p> 0.1 to 3 mcg/kg/minute</td> <td> <ul> <li>Continuous monitoring using an intra-arterial catheter is necessary</li> <li>Cyanide accumulation may occur</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="5">Other antihypertensive agents</td> </tr> <tr> <td class="indent1">Fenoldopam</td> <td>Selective agonist for D<sub>1</sub> dopamine receptors; binds with moderate affinity to alpha<sub>2</sub>-adrenoceptors</td> <td>N/A</td> <td>Initial dose at 0.1 mcg/kg/minute titrated up to a maximum of 1.6 mcg/kg/minute</td> <td> <ul> <li>Rarely used in perioperative settings</li> <li>Generally avoided in patients with glaucoma or increased ICP</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>N/A: not applicable; ICP: intracranial pressure; NO: nitric oxide; SL: sublingual.</p>
<p>* Dose ranges are based on adult patients of average size.</p>
¶ Refer to related UpToDate content on hemodynamic management during anesthesia.</div><div id="graphicVersion">Graphic 119750 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
